Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

Inclusion Criteria: * Age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 * Biopsy proven relapsed or refractory cHL * Prior treatment with at least two systemic therapies * Metabolically active measurable disease by PET imaging per the 2014 Lugano criteria * Hemoglobin ≥ 9.5 g/dL * Absolute neutrophil count ≥ 1,000 cells/μL without G-CSF support within 3 weeks prior to enrollment * Platelet count ≥ 75,000 cells/μL * Creatinine clearance \> 40 mL/min per the Cockroft-Gault formula * Total bilirubin \< 1.5 x upper limit of normal (ULN) (or \< 3.0 x ULN and primarily unconjugated in subjects with a history of Gilbert's syndrome) * Negative urine or serum pregnancy test within 30 days of enrollment and within 72 hours before the first administration of magrolimab for women of childbearing potential * Women of childbearing potential must be willing to use at least 1 highly effective method of contraception during the study and continue for 4 months after the last dose of magrolimab * Male subjects who are sexually active with a woman of childbearing potential and who have not had vasectomies must be willing to use a barrier method of contraception during the study and for 4 months after the last dose of magrolimab * Ability to understand and the willingness to sign the written IRB approved informed consent document * Must be willing and able to comply with the clinic visits and procedures outlined in the study protocol Exclusion Criteria: * Pri…